Investors say Bavarian Nordic should shelve research efforts
Bavarian Nordic’s disappointing phase III study with a vaccine against RSV should lead the company to focus exclusively on its existing vaccine business, several investors tell Børsen.
Several investors want Bavarian Nordic to park its research efforts and instead focus on its existing vaccine business after the company’s failed RSV study helped send the company’s value down by DKK 3.8bn during Monday trading, reports Danish business daily Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
